1. Generics Bulletin
  3. >>Biosimilars

Sandoz Bolsters US Ophthalmic Portfolio With Aflibercept Approval

Launch Date Of Eylea Biosimilar Uncertain As ‘Complicated’ Court Proceedings Continue

 
• By Dave Wallace

Sandoz has celebrated a US FDA approval for its Enzeevu biosimilar rival to Eylea. However, ongoing court proceedings make launch timing uncertain.

USA flag reflected in eye
Sandoz has received FDA approval for its Enzeevu rival to Eylea • Source: Shutterstock

Sandoz has notched up another US Food and Drug Administration biosimilar approval, this time for its Enzeevu (aflibercept-abzv) rival to Regeneron’s Eylea. However, a complicated intellectual property landscape and court proceedings around the ophthalmic brand mean that launch timing remains uncertain.

Meanwhile, previous Eylea biosimilar FDA approvals granting interchangeability to other aflibercept sponsors are currently blocking Enzeevu

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products